1) Development of the Pancreatic Cancer Collaborative Registry and Risk Assessment Models; 2) Pancreatic Cancer Pre-Validation Reference Set for Serum/Plasma Biomarkers; 3) Effects of Tobacco and Alcohol on Pancreatic Cancer; 4) Enhancing the Biomedical Computing Platform for Pancreatic Cancer Research
- Develop Integrated Biomedical Computing Tools (IBCT) for the better understanding and
treatment of pancreatic cancer by using the power of computer and informatics sciences.
- Continue development of the Pancreatic Cancer Collaborative Registry (PCCR)
infrastructure to act as a repository for socio-demographic, environmental, clinical,
and family history data collected from individuals and interested family members with a
personal and/or family history of pancreatic cancer.
- Participate in an international pancreatic registry known as the PCCR by sharing
information collected for research purposes only, to be used by pancreatic cancer
research collaborators from other institutions.
- Collect and bank excess biological materials (i.e., pancreatic tissue, tumor tissue,
and/or metastatic pancreatic cancer tissue, and/or paraffin-embedded tissue), blood,
and serum from registry participants for future research.
- Establish an infrastructure with core data elements and standardized operating
procedures for specimen collection, processing, and storage for the EDRN Pancreatic
Cancer Working Group project to use as a resource for the development of biomarkers for
the early detection of pancreatic adenocarcinoma.
OUTLINE: This is a multicenter study.
Patients undergo blood and pancreatic tissue collection. Normal, tumor, and/or metastatic
pancreatic cancer tissue, and/or paraffin-embedded tissue from prior surgery or biopsy are
Patients provide or complete personal information about themselves, their medical history,
their diet and lifestyle habits, any past or current environmental exposures, and re-create
their family tree for any cancers that have occurred in any of their family members.
Clinical data is collected annually.
Control participants provide blood samples and complete questionnaires at baseline. Clinical
data is collected annually.
PROJECTED ACCRUAL: A total of 60 patients per group (i.e., cancer cases, healthy controls,
acute biliary obstruction cases, and chronic pancreatitis cases) for a total of 240 patients
will be accrued for EDRN portion of this study. A total of ~5,000 patients will be accrued
to the PCCR portion of this study.
Time Perspective: Prospective
Development of integrated Biomedical Computing Tools
Simon Sherman, PhD
University of Nebraska
United States: Institutional Review Board
|UNMC Eppley Cancer Center at the University of Nebraska Medical Center||Omaha, Nebraska 68198-7680|